Literature DB >> 2295795

Cross-antigenicity between the major surface proteins (ospA and ospB) and other proteins of Borrelia burgdorferi.

W Jiang1, B J Luft, P Munoz, R J Dattwyler, P D Gorevic.   

Abstract

Two of the major surface Ag of Borrelia burgdorferi, the 31-kDa OspA and 34-kDa OspB proteins, are encoded by a 49-kb plasmid. In this study, mAb and monospecific polyclonal antibodies were used to define cross-antigenicity of the OspA and OspB protein to each other and to other lower molecular mass proteins by Western blot analysis. Two mAb studied, 105.5 and 184.1, were directed predominantly against the 31-kDa OspA protein. However, each also reacted with other minor bands, though with different specificities. Using V8 protease digestion and cleavage by cyanogen bromide, we demonstrated that each mAb reacted to the 31-kDa protein differently. Monospecific polyclonal rabbit and human antibodies directed against the 34-, 31-, 22-, and 20-kDa proteins were eluted from blots and used to further corroborate the cross-reactivity among these Ag. Rabbit antibodies to the 31- and 22-kDa Ag gave remarkably similar peptide maps after V8 protease digestion of the 31-kDa OspA protein, as did mAb 184.1, suggesting that this mAb recognized an immunodominant epitope common to the 22- and 31-kDa proteins. It seems likely therefore that the humoral immune response to Borrelia surface Ag may be due to a limited number of cross-reactive epitopes on distinct, but related, gene products.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295795

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Further characterization of a potent immunogen and the chromosomal gene encoding it in the Lyme disease agent, Borrelia burgdorferi.

Authors:  G C Perng; R B LeFebvre; R C Johnson
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

2.  Characterization of the protective antibody response to Borrelia burgdorferi in experimentally infected LSH hamsters.

Authors:  J L Schmitz; R F Schell; S D Lovrich; S M Callister; J E Coe
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

3.  Mapping antibody-binding domains of the major outer surface membrane protein (OspA) of Borrelia burgdorferi.

Authors:  W H Schubach; S Mudri; R J Dattwyler; B J Luft
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

4.  Cross-reactive proteins of Borrelia burgdorferi.

Authors:  H R Bruckbauer; V Preac-Mursic; R Fuchs; B Wilske
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

5.  Recombinant chimeric Borrelia proteins for diagnosis of Lyme disease.

Authors:  M J Gomes-Solecki; J J Dunn; B J Luft; J Castillo; D E Dykhuizen; X Yang; J D Glass; R J Dattwyler
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

6.  Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab.

Authors:  H Li; J J Dunn; B J Luft; C L Lawson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

7.  Molecular and immunological characterization of a novel polymorphic lipoprotein of Borrelia burgdorferi.

Authors:  R Wallich; M M Simon; H Hofmann; S E Moter; U E Schaible; M D Kramer
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

8.  Passive immunizing activity of sera from mice infected with Borrelia burgdorferi.

Authors:  S W Barthold; L K Bockenstedt
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

9.  Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen.

Authors:  W S Probert; R B LeFebvre
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

10.  Surface immunofluorescence assay for diagnosis of Lyme disease.

Authors:  R Cevenini; V Sambri; F Massaria; R Franchini; A D'Antuono; G Borda; M Negosanti
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.